Assessment of surrogacy outcomes for overall survival in oncology based on NICE appraisals and post appraisal evidence

November 1, 2019 Becky Hurt

Previous Article
Disease-specific patient-reported outcome (PRO) instruments for hematologic malignancies (HM)
Disease-specific patient-reported outcome (PRO) instruments for hematologic malignancies (HM)

Next Article
Value assessment of HTA decisions for PD-1/PD-L1 inhibitors in oncology
Value assessment of HTA decisions for PD-1/PD-L1 inhibitors in oncology